Medtronic’s Resolute Integrity stent shows efficacy compared to newer technology

Medtronic has announced clinical data from a new study showing the benefits its Resolute Integrity drug-eluting stent continues to provide for heart patients.

The independent BIO-RESORT study represented the first all-comers analysis to compare the safety and efficacy of newer biodegradable polymer stents to the durable polymer Resolute Integrity stent.

At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity, underlining the continued excellent clinical outcomes of the more established device.

The BIO-RESORT trial was one of the largest studies of its kind and highlights the strong performance of the Medtronic stent in real-world clinical practice.

Dr Martin Rothman, vice-president for medical affairs at Medtronic's coronary and structural heart division, said: "The findings of the BIO-RESORT trial reinforce the optimal design and proven, long-term performance of Resolute Integrity, which continues to meet both the current and future needs of our customers even when compared to the benefits of biodegradable technologies."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.